Enzo M. Veltri
Latina, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Journal: Frontiers in oncology
Published: January 27, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 11, 2022
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Journal: Cancer immunology, immunotherapy : CII
Published: July 06, 2021
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Journal: Therapeutic advances in medical oncology
Published: May 18, 2021
Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma.
Journal: Diagnostics (Basel, Switzerland)
Published: February 25, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Journal: International journal of medical sciences
Published: October 25, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 04, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Journal: Journal for immunotherapy of cancer
Published: August 28, 2020
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Journal: Scientific reports
Published: August 22, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 20, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Journal: Scientific reports
Published: February 02, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Journal: Journal of cellular physiology
Published: November 08, 2019
Last Updated: 09/26/2026